Senores Pharmaceuticals Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2tujmlh0f301o0ze1kfiaxro.pdf

Key Takeaways


Regulated Markets & the US Moat

Swapnil Shah: "Our entire formulation manufacturing is done locally in the US as we speak. In terms of APIs, we procure very small quantities from China and some quantities from Europe. In case of any escalation of tariffs for this region, the impact on our business would be negligible."

CDMO-CMO: The Emerging Second Engine

Swapnil Shah: "As we said, I think we would be able to guide 20%, 30% CAGR going forward. I think very accurate projections we'll be able to give by end of this year, early next year. I'm saying calendar year. That would be the right time for us to kind of give very accurate growth projections for the next year."

Emerging Markets: Volume-Led Turnaround


India Branded Generics: Small Base, Fast Ramp


Margins, Cash Flow & Capex

Sanjay Majmudar: "Negative cash flow is a function of continuous growth and reinvestment. I think it's a bit early for us to tell you that what percentage of the cash would be as a surplus positive cash. Let's wait for a couple of quarters. We have a lot of growth still coming, but we are very confident of continuous positive cash flow from the operations."

Portfolio Resilience & Risk Factors

Swapnil Shah: "I don't foresee anything over and above what the industry risk factors are."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenue growth50% top-line growth over FY25FY26 full year
FY26 PAT growth~100% growth over FY25FY26 full year
H2 weightingSecond half bigger than first half across all business metricsH2 FY26
ANDA launches~15-16 ANDA products launched, majority in H2FY26
Acquired ANDA revenue contributionRevenue from Dr. Reddy's, Breckenridge, Wockhardt portfolios beginsH2 FY26, full impact FY27
US manufacturing Line 3OperationalQ3 FY26
US manufacturing Line 4Installed and operationalEnd of FY26
US capacityExpand from 120 crore units to ~200 crore unitsBy end of FY26
Sterile manufacturing in USSet up after four lines completeAfter FY26
API facility US FDA inspectionInspection expectedQ2 FY27
India branded generics revenueSurpass ₹50 croresFY26
India branded generics presencePan-India field force coverageEnd of FY26
Emerging markets EBITDADouble-digitFY26
Emerging markets EBITDAMid-teens, stabilising at 15%-17% annualisedFY27 / sustainable basis
Emerging markets PATMarginally positiveFY26
Consolidated EBITDA marginStable at 25%-26% on annualised basisSteady state
CapexINR 100-150 crores (revised from INR 250 crores)FY26
Operating cash flowContinuous positive cash flow from operationsOngoing
Revenue mixRegulated markets ~60%-70%, emerging markets ~30%FY26 and FY27
CDMO-CMO growth projection20%-30% CAGRGoing forward

Key Metrics

MetricQ1 FY26
Consolidated revenue₹138 cr, +72% YoY and +15% QoQ
EBITDA₹34 cr, +60% YoY
EBITDA margin24.8%, down ~170 bps YoY, up ~360 bps QoQ
PAT₹21 cr, +95% YoY
Operating cash flow~₹11 cr positive
Regulated markets revenue₹90 cr, +69% YoY and +40% QoQ
Regulated markets EBITDA margin35.5%
Emerging markets revenue₹29 cr, +32% YoY
Emerging markets EBITDA margin6%
Domestic branded generics revenue₹8 cr, >4x YoY
CDMO-CMO revenue~₹28 cr
CDMO-CMO order book$23 million as of beginning of Q2 FY26
USFDA-approved ANDAs~70 as of end of Q1 FY26
Commercially launched ANDAs24 as of June 30, 2025
FY26 ANDA launch plan~15–16 products, majority in H2
Emerging markets product approvals308 as of June 30, 2025
Emerging markets products under registration719
Emerging markets realisation~₹1.8 per unit, up from ₹1.2–1.3 per unit last year
India branded generics monthly revenue run rate~₹2.5 cr, nearly doubled in recent months
FY26 revenue growth guidance50% over FY25
FY26 PAT growth guidance~100% over FY25
Annualised EBITDA margin target25%–26%
Emerging markets sustainable EBITDA margin target15%–17%
US manufacturing capacity expansion120 crore units to ~200 crore units, third line by Q3 FY26, fourth line by end of FY26
Overall capex FY26₹100–150 cr, revised from ₹250 cr earlier
Tax rate~20% on average